Cleared Special

K233170 - cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP) (FDA 510(k) Clearance)

Also includes:
cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP-L) cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX) cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX-L)

Class II Neurology device cleared through the Special 510(k) pathway - typically does not require clinical trials.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2023
Decision
29d
Days
Class 2
Risk

K233170 is an FDA 510(k) clearance for the cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP). Classified as Device, Surgical, Cryogenic (product code GXH), Class II - Special Controls.

Submitted by AtriCure, Inc. (Mason, US). The FDA issued a Cleared decision on October 26, 2023 after a review of 29 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.4250 - the FDA neurology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all AtriCure, Inc. devices

Submission Details

510(k) Number K233170 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 27, 2023
Decision Date October 26, 2023
Days to Decision 29 days
Submission Type Special
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
119d faster than avg
Panel avg: 148d · This submission: 29d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code GXH Device, Surgical, Cryogenic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.4250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.